Ulcerative Colitis Patients Resistant to Treatment May Find Golimumab a Viable Therapeutic Option

Ulcerative Colitis Patients Resistant to Treatment May Find Golimumab a Viable Therapeutic Option
Golimumab (symponi) is the latest addition to TNF-α blocking drugs for inflammatory bowel diseases (IBD) such as ulcerative colitis (UC). A summary of all available safety and efficacy data on the drug was recently published in the journal Drug, Healthcare and Patient Safety, concluding the face that golimumab presents a valid treatment option for UC patients refractory

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Is this drug FDA approved in the United States and what is name of drug it is sold as? I note the review was done out of Rome, Italy. Also, any evidence of efficacy in the treatment of Crohn’s Disease.

    Stephen Marcus
    Boston, Massachusetts USA

Leave a Comment

Your email address will not be published. Required fields are marked *